SEC v. Bruce Schoengood; Medifirst Solutions, Inc.; and Joshua Tyrell, No. 2:21-cv-00979, Eastern District of New York (July 18, 2022) — Complaint

RICHARD R. BEST
REGIONAL DIRECTOR
Lara S. Mehraban
Gerald A. Gross
Preethi Krishnamurthy
Eric M. Schmidt
Attorneys for the Plaintiff
SECURITIES AND EXCHANGE COMMISSION
New York Regional Office
Brookfield Place
200 Vesey Street, Suite 400
New York, New York 10281-1022
(212)336-0116 (Krishnamurthy)
[email protected]
UNITED STATES DISTRICT COURT
EASTERN DISTRICT OF NEW YORK
SECURITIES AND EXCHANGE
COMMISSION,
Plaintiff,
-against-
BRUCE SCHOENGOOD, MEDIFIRST
SOLUTIONS, INC., AND JOSHUA TYRELL,
Defendants.
COMPLAINT
21 Civ. 00979 (     )
JURY TRIAL DEMANDED
Plaintiff Securities and Exchange Commission (“Commission”), for its Complaint against
defendants Bruce Schoengood (“Schoengood”), Medifirst Solutions, Inc. (“Medifirst”), and Joshua
Tyrell (“Tyrell”) (collectively, “Defendants”), alleges as follows:
SUMMARY
1.From at least December 2016 through May 2017, Schoengood, Medifirst’s president
and chief executive officer; Medifirst; and Tyrell, a stock promoter, engaged in a fraudulent scheme
designed to evade certain registration requirements of the federal securities laws. In addition, from

2

August through November 2017, Schoengood engaged in a separate scheme to manipulate the price
of Medifirst’s stock.
2. In approximately December 2016, Medifirst, through Schoengood, and Tyrell
entered into a sham agreement. Under the agreement’s terms, Tyrell would purportedly provide
“business development” consulting services to Medifirst. In return, Medifirst would issue 11 million
shares of its stock (later amended to include 9 million additional shares) to Tyrell upon registering
the issuance with the Commission on Form S-8, a registration form that permits securities issuers to
register certain issuances of stock—but not stock paid in compensation for stock promotion services.
3. In reality, as Tyrell and Schoengood knew, Tyrell never provided any business
consulting services to Medifirst. Through Schoengood, Medifirst in fact issued stock to Tyrell as
compensation for promoting Medifirst stock to potential investors through a stock promotion entity
(“Promoter A”) affiliated with Tyrell.
4. Because Form S-8 did not permit registration of stock issuances for such purposes,
Schoengood and Tyrell, among other things, falsely represented to Tyrell’s brokerage firm that Tyrell
was receiving Medifirst stock as compensation for business development services and that Tyrell
was not involved in promoting Medifirst stock.
5. Of the 20 million Medifirst shares he received, Tyrell later sold over 19 million
shares to unwitting investors in the public market without registration for proceeds of approximately
$125,000.
6. In addition, from August through November 2017, Schoengood arranged, through
another stock promoter (“Promoter B”), to have a third-party purchase Medifirst stock in exchange
for cash payments in order to manipulate the market price of Medifirst stock.

3

VIOLATIONS
7. By virtue of the conduct alleged in this Complaint, Schoengood violated Sections
5(a), 5(c), 17(a)(1) and 17(a)(3) of the Securities Act of 1933 (“Securities Act”) [15 U.S.C. §§ 77e(a),
77e(c), 77q(a)(1) and 77q(a)(3)], Sections 9(a)(2) and 10(b) of the Securities Exchange Act of 1934
(“Exchange Act”) [15 U.S.C. §§ 78i(a)(2) and 78j(b)], and Rule 10b-5 promulgated thereunder
[17 C.F.R. § 240.10b-5].
8. By virtue of the conduct alleged in this Complaint, Medifirst violated Securities Act
Sections 5(a), 5(c), 17(a)(1) and 17(a)(3) [15 U.S.C. §§ 77e(a), 77e(c), 77q(a)(1) and 77q(a)(3)],
Exchange Act Section 10(b) [15 U.S.C. § 78j(b)], and Rule 10b-5 [17 C.F.R. § 240.10b-5].
9. By virtue of the conduct alleged in this Complaint, Tyrell violated Securities Act
Sections 5(a), 5(c), 17(a)(1), 17(a)(2) and 17(a)(3) [15 U.S.C. §§ 77e(a), 77e(c), 77q(a)(1), 77q(a)(2) and
77q(a)(3)], Exchange Act Section 10(b) [15 U.S.C. § 78j(b)], and Rule 10b-5 [17 C.F.R. § 240.10b-5].
10. Unless Defendants are restrained and enjoined, they will again engage in the acts,
practices, transactions, and courses of business set forth in this Complaint or in acts, practices,
transactions, and courses of business of similar type and object.
NATURE OF THE PROCEEDINGS AND RELIEF SOUGHT
11. The Commission brings this action pursuant to the authority conferred upon it by
Securities Act Sections 20(b) and 20(d) [15 U.S.C. §§ 77t(b) and 77t(d)] and Exchange Act Section
21(d) [15 U.S.C. § 78u(d)].
12. The Commission seeks a final judgment: (a) permanently enjoining Defendants from
violating the federal securities laws and rules this Complaint alleges they have violated; (b) ordering
Tyrell to disgorge the ill-gotten gains he received as a result of the violations alleged herein and to
pay prejudgment interest thereon, pursuant to Exchange Act Section 21(d)(5) [15 U.S.C. § 78u(d)(5)]
and Sections 6501(a)(1) and (a)(3) of the National Defense Authorization Act for Fiscal Year 2021,

4

Pub. L. No. 116-283, to be codified at 15 U.S.C. §§ 78u(d)(3) and 78u(d)(7); (c) ordering
Schoengood and Tyrell to pay civil money penalties, pursuant to Securities Act Section 20(d) [15
U.S.C. § 77t(d)] and Exchange Act Section 21(d)(3) [15 U.S.C. § 78u(d)(3)]; (d) permanently
prohibiting Schoengood from serving as an officer or director of any company that has a class of
securities registered under Exchange Act Section 12 [15 U.S.C. § 78l] or that is required to file
reports under Exchange Act Section 15(d) [15 U.S.C. § 78o(d)], pursuant to Securities Act Section
20(e) [15 U.S.C. § 77t(e)] and Exchange Act Section 21(d)(2) [15 U.S.C. § 78u(d)(2)]; (e) permanently
prohibiting Schoengood and Tyrell from participating in any offering of a penny stock, pursuant to
Exchange Act Section 21(d)(6) [15 U.S.C. § 78u(d)(6)]; and (f) ordering any other relief the Court
may deem just and proper.

JURISDICTION AND VENUE
13. This Court has jurisdiction over this action under Securities Act Section 22(a)
[15 U.S.C. § 77v(a)] and Exchange Act Section 27 [15 U.S.C. § 78aa].
14. Defendants, directly or indirectly, have made use of the means or instrumentalities of
interstate commerce or of the mails in connection with the transactions, acts, practices, and courses
of business alleged herein.
15. Venue lies in this District under Securities Act Section 22(a) [15 U.S.C. § 77v(a)] and
Exchange Act Section 27 [15 U.S.C. § 78aa]. Among other things, orders for the manipulative trades
alleged here were placed in Nassau County in the Eastern District of New York. In addition,
investors residing in the Eastern District of New York, including investors residing in Brooklyn or
Queens, bought Medifirst stock on days that Tyrell sold shares into the public market and on days
that Schoengood had arranged for manipulative trading in Medifirst stock.

5


THE DEFENDANTS
16. Schoengood, age 62, is a resident of Manalapan, New Jersey, and has been
Medifirst’s CEO since at least 2011.
17. Medifirst is a Nevada corporation with its principal office in Freehold, New Jersey.
Medifirst currently claims to be marketing a “Laser Thermal Therapeutic Device.” From December
2016 through November 2017 (the “Relevant Period”), Medifirst’s common stock was quoted under
the symbol “MFST” on OTC Link, an interdealer quotation and trade messaging system operated by
OTC Markets Group, Inc. During the Relevant Period, Medifirst’s common stock met the definition
of a “penny stock” under Exchange Act Section 3(a)(51) [15 U.S.C. § 78c(a)(51)] and Rule 3a51-1
thereunder [17 C.F.R. § 240. 3a51-1], in part because the stock traded below five dollars per share.
18. Tyrell, age 36, is a resident of Huntington Beach, California. From at least
December 2016 through May 2017, Tyrell was associated with Promoter A, a California-based stock
promotion firm.
LEGAL FRAMEWORK: RELEVANT REGISTRATION REQUIREMENTS
19. Congress enacted the Securities Act to regulate the offer and sale of securities.
20. In contrast to ordinary commerce, Congress enacted a regime of full and fair
disclosure, requiring those who offer and sell securities to the investing public to provide sufficient,
accurate information to allow investors to make informed decisions before they invest.
21. A registration statement is a filing with the Commission making the required
disclosures in connection with the registration of a securities offering (among other types of
registration). Such registration statements provide public investors with information about the
securities issuer and the offering.

6

22. Securities Act Sections 5(a) and 5(c) prohibit the offer or sale of securities in
interstate commerce without registration, absent a valid exemption from registration.
23. Commission Form S-8 is a short-form registration statement to register certain
offerings or issuances of a public company’s securities to people (“natural persons,” not entities)
who provide “bona fide services” to the company as long as the services “do not directly or
indirectly promote or maintain a market for the” securities. An issuer cannot use Form S-8 to
register the issuance of stock in compensation for stock promotion services.
24. A Form S-8 registration statement is not valid if it is used to register a stock offering
that does not meet the requirements for using a Form S-8 registration statement. For example, a
Form S-8 registration statement is not valid if it is used to register stock paid in compensation for
stock promotion services.
25. Under certain conditions, a person who receives stock through an issuance registered
on a valid Form S-8 statement may resell that stock in the public market without the filing of any
further registration statement. This is because most market transactions are covered by a common
registration exemption.
26. Sometimes companies issue stock in unregistered “private” transactions. In such
cases, the stock certificate typically carries a restrictive legend preventing its resale in an unregistered,
non-exempt transaction.
FACTS
I.   DEFENDANTS ENGAGED IN A FRAUDULENT SCHEME TO SELL
MEDIFIRST STOCK TO THE PUBLIC IN AN UNREGISTERED OFFERING.
27. In the fall of 2016, Schoengood arranged to have the stock promotion firm Tyrell
worked for, Promoter A, promote Medifirst stock by soliciting retail investors by telephone to
purchase the stock in the public market.

7

28. Schoengood arranged with Promoter A to use Tyrell as a conduit to receive Medifirst
shares as compensation for Promoter A’s promotion of Medifirst stock.
29. Under the arrangement, Medifirst’s issuance of shares was to be registered on
Commission Form S-8
to enable Medifirst to issue the stock to Tyrell without any restrictive
legend—that is, without any legend making clear that the shares cannot be resold into the public
markets without meeting certain requirements. That way, Tyrell could immediately sell the shares he
received to the public through market transactions.
A. The Purported Consulting Agreement and Tyrell’s First 7.9 Million Shares
30. On December 8, 2016, Medifirst and Tyrell executed a purported consulting
agreement (the “Consulting Agreement”).
31. Under the Consulting Agreement’s terms, Tyrell purported to act as a “business
development” consultant to Medifirst for six months in exchange for 11 million shares of Medifirst
common stock in an issuance that Medifirst would register on Form S-8.
32. The Consulting Agreement purported to require Tyrell “not [to] conduct any
meetings with any prospective financial investors” in Medifirst.
33. Tyrell and Schoengood, on Medifirst’s behalf, signed the Consulting Agreement.
34. On December 8, 2016, the same day Tyrell and Medifirst executed the Consulting
Agreement, Medifirst filed a Form S-8 registration statement with the Commission, purporting to
register Medifirst’s issuances of 32 million shares of Medifirst stock to employees and consultants,
pursuant to Medifirst’s “MFST Equity Incentive Plan” (the “Incentive Plan”).
35. At the time, the instructions to the Commission’s Form S-8 made clear to companies
issuing stock that the Form S-8 could only be used to register securities issuances to people (“natural
persons”) who provide “bona fide services” to the company issuing the stock when the services “do
not directly or indirectly promote or maintain a market for the” company’s securities.

8

36. Also on December 8, 2016, Schoengood signed a “Written Consent of the Sole
Director of Medifirst Solutions, Inc.” (the “December 8 Consent”), authorizing the issuance of 11
million shares of Medifirst stock to Tyrell.
37. The December 8 Consent claimed that the shares were issued under the Incentive
Plan “in connection with consulting services provided by [Tyrell].”
38. The December 8 Consent also stated that the issuance of stock under the Incentive
Plan “has been or will be registered on Form-8 with the SEC.”
39. Also on December 8, 2016, in a letter emailed to Medifirst’s transfer agent (the
“Transfer Agent”), Schoengood instructed the Transfer Agent to issue 7.9 million shares of
Medifirst stock to Tyrell under the Incentive Plan.
40. In his letter, Schoengood represented that the shares had been “issued for services
rendered and registered pursuant to a registration statement on Form S-8” and therefore that the
shares would be “free-trading and need not bear the standard 1933 Act legend,” apparently referring
to a legend that would have made clear that the shares could not be sold or transferred without
further registration or an exemption from registration.
41. Schoengood’s letter bore a signature block identifying him as Medifirst’s chief
executive officer.
42. Tyrell then arranged to have the 7.9 million Medifirst shares deposited into his
account at a brokerage firm (the “Brokerage Firm”).
43. Specifically, on approximately December 9, 2016, Tyrell submitted an application to
the Brokerage Firm to accept the deposit of 7.9 million Medifirst shares into his account at the
Brokerage Firm.
44. In his application, Tyrell represented to the Brokerage Firm that the Medifirst stock
had been issued to him as compensation for “business development” services.

9

45. On December 9, 2016, Tyrell emailed the Brokerage Firm’s registered representative
assigned to Tyrell’s account (the “Registered Representative”).
46. In his email to the Registered Representative, Tyrell claimed that he was “not
involved or aware in [sic] any stock promotion with Medifirst.”
47. On approximately the same day, Tyrell provided the Brokerage Firm with a copy of
the Consulting Agreement, the December 8 Consent and Medifirst’s December 8 instructions to the
Transfer Agent.
48. On December 12, 2016, Tyrell sent an email to the Transfer Agent and to the
Registered Representative, attaching a copy of a legal opinion letter dated December 8, 2017 (the
“December 8 Opinion Letter”), addressed to the Transfer Agent,
49. The December 8 Opinion Letter stated that 7.9 million Medifirst shares “may be
issued to [Tyrell] without a restrictive legend” and that Tyrell “may sell the [Medifirst shares] free of
any restrictions on transfer without registration under the Securities Act pursuant to the [Form S-8
registration].”
50. The December 8 Opinion Letter also instructed the Transfer Agent to issue the
shares without a restrictive legend.
51. The same day, Schoengood sent an email to Tyrell, directed to the Brokerage Firm.
52. In his email, Schoengood claimed: “Mr. Tyrell has been engaged as a consultant to
the company and as per our Consulting Agreement, his duties are not related to fundraising, [stock]
market awareness, or Investor Relations.”
53. Schoengood’s email bore a signature block identifying him as Medifirst’s president.
54. About an hour later, Tyrell forwarded Schoengood’s email to the Brokerage Firm’s
Registered Representative.

10

55. Two days later, on December 14, 2016, the Transfer Agent issued 7.9 million
Medifirst shares to Tyrell without a restrictive legend.
56. As Tyrell had arranged, those shares were deposited into his Brokerage Firm
account.
B. Tyrell’s Second Installment of 3.1 Million Shares
57. On January 17, 2017, in a letter emailed to the Transfer Agent, Schoengood
instructed the Transfer Agent to issue an additional 3.1 million shares of Medifirst stock to Tyrell
under the Incentive Plan, as already authorized by the December 8 Consent.
58. In his letter, Schoengood represented that the shares had been “issued for services
rendered and registered pursuant to a registration statement on Form S-8” and therefore that the
shares would be “free-trading and need not bear the standard 1933 Act legend.”
59. Schoengood’s letter bore a signature block identifying him as Medifirst’s chief
executive officer.
60. On approximately January 19, 2017, Tyrell provided the Transfer Agent with a legal
opinion letter dated January 19, 2017 (the “January 19 Opinion Letter”), addressed to the Transfer
Agent, that 3.1 million Medifirst shares “may be issued to [Tyrell] without a restrictive legend” and
that Tyrell “may sell the [Medifirst shares] free of any restrictions on transfer without registration
under the Securities Act pursuant to the [Form S-8 registration].”
61. The January 19 Opinion Letter instructed the Transfer Agent to issue the shares
without a restrictive legend.
62. On approximately January 19, 2017, Tyrell submitted an application to the Brokerage
Firm to accept his deposit of 3.1 million Medifirst shares into his account at the Brokerage Firm.
63. In his application, Tyrell represented to the Brokerage Firm that the Medifirst stock
had been issued to him as compensation for “business development” services.

11

64. On approximately the same day, Tyrell provided the Brokerage Firm with copies of
the January 19 Opinion Letter and Medifirst’s January 19 instructions to the Transfer Agent.
65. Also on approximately the same day, Tyrell sent an email to the Brokerage Firm’s
Registered Representative and claimed: “I Joshua Tyrell, am not involved in any stock promotion or
capital raising with Medifirst.”
66. On January 24, 2017, the Transfer Agent issued 3.1.million Medifirst shares to Tyrell.
67. As Tyrell had arranged, those shares were deposited into his account at the
Brokerage Firm.
C. Tyrell’s Third Installment of 5 Million Shares
68. On February 2, 2017, Medifirst and Tyrell amended the Consulting Agreement to
provide for the issuance of an additional 5 million Medifirst shares to Tyrell.
69. Schoengood, on Medifirst’s behalf, and Tyrell signed the amended agreement.
70. On February 3, 2017, in a letter he emailed to the Transfer Agent, Schoengood
instructed the Transfer Agent to issue an additional 5 million shares of Medifirst stock to Tyrell
under the Incentive Plan and represented that the shares had been “issued for services rendered and
registered pursuant to a registration statement on Form S-8” and therefore that the shares would be
“free-trading and need not bear the standard 1933 Act legend.”
71. Schoengood’s letter bore a signature block identifying him as Medifirst’s chief
executive officer.
72. On February 3, 2017, Schoengood provided the Transfer Agent with a “Written
Consent of the Sole Director of Medifirst Solutions, Inc.” (the “February 3 Consent”) signed by
Schoengood, authorizing the issuance of 5 million shares of Medifirst stock to Tyrell.
73. The February 3 Consent claimed that the shares were issued under the Incentive
Plan “in connection with consulting services provided by [Tyrell].”

12

74. The February 3 Consent also stated that the issuance of stock under the Incentive
Plan “has been or will be registered on Form-8 with the SEC.”
75.  On approximately February 3, 2017, Tyrell provided the Transfer Agent with a legal
opinion letter dated February 3, 2017 (“February 3 Opinion Letter”), addressed to the Transfer
Agent, that 5 million Medifirst shares “may be issued to [Tyrell] without a restrictive legend” and
that Tyrell “may sell the [Medifirst shares] free of any restrictions on transfer without registration
under the Securities Act pursuant to the [Form S-8 registration].”
76. The February 3 Opinion Letter instructed the Transfer Agent to issue the shares
without a restrictive legend.
77. On approximately February 6, 2017, Tyrell submitted an application to the
Brokerage Firm to accept the deposit of 5 million Medifirst shares into Tyrell’s account at the
Brokerage Firm.
78. In his application, Tyrell represented to the Brokerage Firm that the Medifirst stock
had been issued to him as compensation for “business development” services.
79. On approximately February 6, 2017, Tyrell provided the Brokerage Firm with a copy
of the February 3 Consent, Medifirst’s February 3, 2017 instructions to the Transfer Agent, and the
February 3 Opinion Letter.
80. On February 6, 2017, Tyrell sent an email to the Brokerage Firm’s Registered
Representative and claimed: “I am not involved in any capital raising with [Medifirst].”
81. On February 7, 2017, the Transfer Agent issued 5 million Medifirst shares to Tyrell.
82. As Tyrell had arranged, the 5 million shares were deposited into his account at the
Brokerage Firm.

13

D. Tyrell’s Fourth Installment of 4 Million Shares
83. On March 1, 2017, Medifirst and Tyrell amended the Consulting Agreement again to
provide for the issuance of an additional 4 million Medifirst shares to Tyrell.
84. On March 2, 2017, Schoengood signed a “Written Consent of the Sole Director of
Medifirst Solutions, Inc.” (the “March 2 Consent”), authorizing the issuance of 4 million shares of
Medifirst stock to Tyrell.
85. The March 2 Consent claimed that the shares were issued under the Incentive Plan
“in connection with consulting services provided by [Tyrell].”
86. The March 2 Consent also stated that the issuance of stock under the Incentive Plan
“has been or will be registered on Form-8 with the SEC.”
87. On March 2, 2017, in a letter he emailed to the Transfer Agent, Schoengood
instructed the Transfer Agent to issue an additional 4 million shares of Medifirst stock to Tyrell
under the Incentive Plan, and represented that the shares had been “issued for services rendered and
registered pursuant to a registration statement on Form S-8” and therefore that the shares would be
“free-trading and need not bear the standard 1933 Act legend.”
88. Schoengood’s letter bore a signature block identifying him as Medifirst’s chief
executive officer.
89. On that date, Tyrell provided to the Transfer Agent a legal opinion letter dated
March 1, 2017 (the “March 1 Opinion Letter”), addressed to the Transfer Agent, that 4 million
Medifirst shares “may be issued to [Tyrell] without a restrictive legend” and that Tyrell “may sell the
[Medifirst shares] free of any restrictions on transfer without registration under the Securities Act
pursuant to the [Form S-8 registration].”
90. The March 1 Opinion Letter instructed the Transfer Agent to issue the shares
without a restrictive legend.

14

91. On approximately March 2, 2017, Tyrell submitted an application to the Brokerage
Firm to accept the deposit of 4 million Medifirst shares into his account at the Brokerage Firm.
92. In his application, Tyrell represented to the Brokerage Firm that the Medifirst stock
had been issued to him as compensation for “Product Marketing and Ongoing Business
Development.”
93. On approximately March 2, 2017, Tyrell provided the Brokerage Firm with a copy of
the March 2 Consent, Medifirst’s March 2, 2017 instructions to the Transfer Agent, and the March 1
Opinion Letter.
94. Also on March 2, 2017, Tyrell sent an email to the Brokerage Firm’s Registered
Representative and again claimed: “I am not aware or involved in any stock promotion or capital
raising with Medifirst Solutions, Inc.”
95. On March 6, 2017, the Transfer Agent issued 4 million Medifirst shares to Tyrell.
96. As Tyrell had arranged, the 4 million shares were deposited into his account at the
Brokerage Firm.
E. Tyrell’s Sales of the Shares and Phone Call with Schoengood
97. From December 16, 2016 through May 1, 2017, Tyrell sold at least 19 million of the
20 million Medifirst shares issued to him pursuant to the purported Consulting Agreement into the
public market.
98. Tyrell received about $125,000 in proceeds from these sales.
99. On December 5, 2017, Tyrell spoke to Schoengood by telephone to discuss Tyrell’s
stock promotion activities.
100. In this call, Tyrell described how the salesmen at Promoter A called potential
investors and started selling stock:
[I]t takes a week or two for my guys to really start ramping up . . . start
building the momentum. That’s how it kind of works with the phone calls.

15

You start with one, two, ten people . . . they get other people. You talk about
it, then they see it start trading, then they start jumping on it and chase it.
You know how psychology works.
II.   SCHOENGOOD MADE MANIPULATIVE TRADES IN MEDIFIRST STOCK.
101. Prior to 2017, Promoter B, another stock promoter, told Schoengood that Promoter
B knew a broker who would buy Medifirst stock in exchange for a cash kickback (the “Buyer”).
102. From August 1, 2016 through August 22, 2017, the price of Medifirst stock ranged
from $0.012 to $0.0016 per share in reported transactions.
103. During the same period, the daily trading volume of Medifirst stock ranged from
61,000 shares to 64,882,000 shares in reported transactions.
104. On six occasions from August 23, 2017 through November 2017, Schoengood
arranged through Promoter B to have the Buyer purchase over 10.6 million shares of Medifirst stock
in total in order to keep the price of Medifirst stock from falling.
105. On August 23, 2017, the price of Medifirst stock opened at $0.0016 per share.
106. That day, the lowest reported price at which Medifirst stock traded was $0.0015 per
share.
107. On August 23, 2017, Schoengood and Promoter B spoke by telephone.
108. On that call, Schoengood asked Promoter B to arrange for the Buyer to buy 500,000
shares of Medifirst stock.
109. The same day, after the call, the Buyer purchased 500,000 Medifirst shares at $0.0017
per share.
110. That same day, the highest reported price at which Medifirst stock traded was
$0.0017 per share.
111. Two days later, on August 25, 2017, Schoengood spoke to Promoter B by telephone.

16

112. On that call, Schoengood explained to Promoter B that he was using the Buyer’s
purchases to keep Medifirst’s share price from falling: “I’d rather use your fire power when we need
it to hold [Medifirst’s share price] . . . . I don’t want it to dip less than .0017 . . . . Let’s try and hold it
there.”
113. On September 11, 2017, the price of Medifirst stock opened at $0.0016 per share.
114. That day, the lowest reported price for Medifirst stock was $0.0015 per share.
115. On September 11, 2017, Schoengood spoke to Promoter B by telephone.
116. On that call, Schoengood asked Promoter B to arrange for the purchase of Medifirst
stock to “support” Medifirst’s stock price: Schoengood asked Promoter B to “contribute a little bit”
and “make sure there’s a little support” for Medifirst’s share price.
117. That day, following the call, the Buyer purchased 500,000 Medifirst shares at $0.0016
per share.
118. That day, the highest reported price for Medifirst stock was $0.0016 per share.
119. The following month, on October 24, 2017, Schoengood spoke to Promoter B by
telephone.
120. On that call, Schoengood asked Promoter B to have the Buyer make some purchases
as soon as possible “because I think we need a little boost.”
121. The next day, on October 25, 2017, the price of Medifirst stock opened at $0.0012
per share.
122. The lowest reported price at which Medifirst stock traded that day was also $0.0012
per share.
123. On October 25, 2017, the Buyer purchased approximately 3.4 million shares of
Medifirst stock—over 40% of the total reported volume of Medifirst shares that traded that day—at
$0.0013 per share.

17

124. The day after that, on October 26, 2017, the price of Medifirst stock opened at
$0.0012 per share.
125. The lowest reported price at which Medifirst stock traded that day was also $0.0012
per share.
126. On October 26, 2017, Schoengood again asked Promoter B to arrange for the Buyer
to purchase Medifirst stock.
127. Later on October 26, 2017, the Buyer purchased approximately 579,000 shares of
Medifirst stock—almost 25% of the total reported volume of Medifirst shares that traded that day—
at $0.0013 per share.
128. The next day, on October 27, 2017, the price of Medifirst stock opened at $0.0012
per share.
129. That day, the lowest reported price at which Medifirst stock traded was also $0.0012
per share.
130. On October 27, 2017, Schoengood spoke to Promoter B on the telephone.
131. During the call, Schoengood told Promoter B that “[w]e want to get some [.0013]
bids in there.”
132. On the same call, Schoengood explained that he wanted “to tighten it up a little bit
and then take some more of the [.0014]. If we hit the [.0012] then we are right back down.”
133. Promotor B asked Schoengood: “So bid a little [.0013] and then take out some
[.0014]?” Schoengood responded: “[E]xactly.”
134. Later that day, the Buyer purchased approximately 2.8 million additional shares of
Medifirst stock—over 70% of the total reported volume of Medifirst shares that traded that day—at
$0.0013 per share.
135. On November 13, 2017, Schoengood met with Promoter B.

18

136. During the meeting Schoengood asked Promoter B about the Buyer and asked
Promoter B: “Can we bring him back?”
137. Promoter B explained that they would have to pay the Buyer kickbacks for prior
trading.
138. Schoengood replied: “Do me a favor, get him [the Buyer] going again.”
139. On November 15, 2017, the price of Medifirst stock opened at $0.001 per share.
140. That day, the lowest reported price at which Medifirst stock traded was $0.0008 per
share.
141. On November 15, 2017, the Buyer purchased another 3 million shares of Medifirst
stock at $0.001 per share.
142. On November 17, 2017, Schoengood met with Promoter B and gave Promoter B
$1,600 to be paid as a kickback to the Buyer for the Buyer’s purchase of Medifirst shares.
143. After the Buyer ceased buying Medifirst’s stock, its price declined steadily.
144. By July 20, 2018, the trading day before Medifirst implemented a reverse stock split
at a ratio of 1-to-1000 shares (meaning every 1,000 shares were consolidated into a single share),
Medifirst’s closing stock price had dropped to $0.0002 per share.
FIRST CLAIM FOR RELIEF
Violations of Securities Act Sections 17(a)(1) and 17(a)(3)
(All Defendants)

145. Paragraphs 1 through 144 are realleged and incorporated by reference as if fully set
forth herein.
146. Schoengood, Medifirst and Tyrell, directly or indirectly, singly or in concert, in the
offer or sale of securities, by the use of the means or instruments of transportation or
communication in interstate commerce, or by use of the mails, (a) have employed, are employing, or
are about to employ, devices, schemes, or artifices to defraud; and/or (b) have engaged, are

19

engaging, or are about to engage in transactions, practices, or courses of business which operate,
operated, or would operate as a fraud or deceit upon the purchasers of securities, in violation of
Sections 17(a)(1) and 17(a)(3) of the Securities Act [Section 15 U.S.C. §§ 77q(a)(1) and 77q(a)(3)].
SECOND CLAIM FOR RELIEF
Violations of Securities Act Section 17(a)(2)
(Tyrell)

147. Paragraphs 1–5, 9–100 are realleged and incorporated by reference as if fully set
forth herein.
148. Tyrell, directly or indirectly, singly or in concert, in the offer or sale of securities, by
the use of the means or instruments of transportation or communication in interstate commerce, or
by use of the mails, (a) has obtained, is obtaining, or is about to obtain, money or property by means
of an untrue statement of a material fact or an omission of a material fact necessary in order to make
the statements made, in light of the circumstances under which they were made, not misleading, in
violation of Section 17(a)(2) of the Securities Act [Section 15 U.S.C. § 77q(a)(2)].
THIRD CLAIM FOR RELIEF
Violations of Exchange Act Section 10(b) and Rule 10b-5 Thereunder
(All Defendants)

149. Paragraphs 1 through 144 are realleged and incorporated by reference as if fully set
forth herein.
150. Schoengood, Medifirst and Tyrell, directly or indirectly, singly or in concert, in
connection with the purchase or sale of securities and by the use of the means or instrumentalities of
interstate commerce, of the mails, or of the facilities of a national securities exchange, knowingly or
recklessly (a) have employed, are employing or are about to employ devices, schemes and artifices to
defraud; (b) have made, are making or are about to make an untrue statement of a material fact or to
omit to state a material fact necessary in order to make the statements made, in the light of the
circumstances under which they were made, not misleading; and/or c) have engaged, are engaging or

20

are about to engage in transactions, practices or courses of business which have operated, operate or
will operate as a fraud and deceit upon investors, in violation of Exchange Act Section 10(b) [15
U.S.C. § 78j(b)] and Rule 10b-5 thereunder [17 C.F.R. §§ 240.10b-5].
FOURTH CLAIM FOR RELIEF
Violations of Exchange Act Section 9(a)(2)
(Schoengood)

151. Paragraphs 1, 6–7, 10–17, and 101–144 are realleged and incorporated by reference
as if fully set forth herein.
152. Schoengood, directly or indirectly, singly or in concert, by use of the means or
instruments of transportation or communication in, or the means or instrumentalities of, interstate
commerce or by the use of the mails, knowingly or recklessly, is effecting, has effected or is about to
effect, a series of transactions in securities with respect to such security creating actual or apparent
active trading in such security, or raising or depressing the price of such security, for the purpose of
inducing the sale of such security by others, in violation of Exchange Act Section 9(a)(2) [15 U.S.C.
§78i(a)(2)].
FIFTH CLAIM FOR RELIEF
Violations of Securities Act Sections 5(a) and (c)
(All Defendants)

153. Paragraphs 1–5 and 7–100 are realleged and incorporated by reference as if fully set
forth herein.
154. Schoengood, Medifirst and Tyrell, directly or indirectly, singly or in concert, in the
offer or sale of securities, by the use of the means or instruments of transportation or
communication in interstate commerce, or by use of the mails, (a) have sold securities without a
registration statement being in effect as to those securities through the medium of a prospectus or
otherwise; and (b) have offered to sell or offered to buy through the medium of a prospectus or

21

otherwise a security, without a registration statement having been filed with the Commission as to
such security, in violation of Securities Act Sections 5(a) and 5(c) [15 U.S.C. §§ 77e(a) and (c)].
PRAYER FOR RELIEF
WHEREFORE, the Commission respectfully requests a Final Judgment:
I.
Permanently enjoining Defendants Schoengood, Medifirst, and Tyrell, and their agents,
servants, employees, and attorneys, and all persons in active concert or participation with any of
them who receive actual notice of the final judgment by personal service or otherwise, and each of
them, from future violations of Securities Act Sections 5 and 17(a) [15 U.S.C. §§ 77e and 77q(a)],
Exchange Act Section 10(b) [15 U.S.C. § 78j(b)] and Rule 10b-5 promulgated thereunder [17 C.F.R.
§ 240.10b-5];
II.
Permanently enjoining Defendant Schoengood, and his agents, servants, employees, and
attorneys, and all persons in active concert or participation with any of them who receive actual
notice of the final judgment by personal service or otherwise, and each of them, from future
violations of Exchange Act Section 9(a) [15 U.S.C. §§ 78i(a)];
III.
Ordering Defendant Tyrell to disgorge all ill-gotten gains he received directly or indirectly,
with prejudgment interest thereon, as a result of his violations alleged in this Complaint, pursuant to
Exchange Act Section 21(d)(5) [15 U.S.C. § 78u(d)(5)] and Sections 6501(a)(1) and (a)(3) of the
National Defense Authorization Act for Fiscal Year 2021, Pub. L. No. 116-283, to be codified at 15
U.S.C. §§ 78u(d)(3) and 78u(d)(7).

22

IV.
Ordering Defendants Schoengood and Tyrell to pay civil money penalties pursuant to
Securities Act Section 20(d) [15 U.S.C. § 78t(d)] and Exchange Act Section 21(d)(3) [15 U.S.C.
§ 78u(d)(3)];
V.
Permanently prohibiting Defendant Schoengood from serving as an officer or director of
any company that has a class of securities registered under Exchange Act Section 12 [15 U.S.C.
§ 78l] or that is required to file reports under Exchange Act Section 15(d) [15 U.S.C. § 78o(d)],
pursuant to Securities Act Section 20(e) [15 U.S.C. § 78t(e)] and Exchange Act Section 21(d)(2)
[15 U.S.C. § 78u(d)(2)];
VI.
Permanently prohibiting Defendants Schoengood and Tyrell from participating in any
offering of a penny stock, including engaging in activities with a broker, dealer, or issuer for
purposes of issuing, trading, or inducing or attempting to induce the purchase or sale of any penny
stock, under Exchange Act Section 21(d)(6) [15 U.S.C. § 78u(d)(6)]; and

23

VII.
Granting any other and further relief as the Court may deem just and proper.
JURY DEMAND
 The Commission demands a trial by jury.
Dated:  New York, New York
 February 23, 2021

_/s/ Richard R. Best__________________
Richard A. Best
      Lara S. Mehraban
Gerald A. Gross
Preethi Krishnamurthy
Eric M. Schmidt

                                                                        SECURITIES            AND            EXCHANGE            COMMISSION
                                                                        New            York            Regional            Office
      Brookfield Place
                                                                        200            Vesey            Street,            Suite            400
                                                                        New            York,            New            York            10281-1022
                                                                        (212)            336-0116            (Krishnamurthy)
                                                                        [email protected]

RICHARD R. BEST 
REGIONAL DIRECTOR 
Lara S. Mehraban 
Gerald A. Gross 
Preethi Krishnamurthy 
Eric M. Schmidt  
Attorneys for the Plaintiff 
SECURITIES AND EXCHANGE COMMISSION 
New York Regional Office 
Brookfield Place 
200 Vesey Street, Suite 400 
New York, New York 10281-1022 
(212) 336-0116 (Krishnamurthy)
[email protected]

UNITED STATES DISTRICT COURT  
EASTERN DISTRICT OF NEW YORK 

SECURITIES AND EXCHANGE 
COMMISSION, 

Plaintiff, 

-against-

BRUCE SCHOENGOOD, MEDIFIRST 
SOLUTIONS, INC., AND JOSHUA TYRELL,  

Defendants. 

COMPLAINT 

21 Civ. 00979 (     ) 

JURY TRIAL DEMANDED 

Plaintiff Securities and Exchange Commission (“Commission”), for its Complaint against 

defendants Bruce Schoengood (“Schoengood”), Medifirst Solutions, Inc. (“Medifirst”), and Joshua 

Tyrell (“Tyrell”) (collectively, “Defendants”), alleges as follows: 

SUMMARY 

1. From at least December 2016 through May 2017, Schoengood, Medifirst’s president

and chief executive officer; Medifirst; and Tyrell, a stock promoter, engaged in a fraudulent scheme 

designed to evade certain registration requirements of the federal securities laws. In addition, from 

Case 2:21-cv-00979   Document 1   Filed 02/23/21   Page 1 of 23 PageID #: 1



2 

August through November 2017, Schoengood engaged in a separate scheme to manipulate the price 

of Medifirst’s stock.  

2. In approximately December 2016, Medifirst, through Schoengood, and Tyrell 

entered into a sham agreement. Under the agreement’s terms, Tyrell would purportedly provide 

“business development” consulting services to Medifirst. In return, Medifirst would issue 11 million 

shares of its stock (later amended to include 9 million additional shares) to Tyrell upon registering 

the issuance with the Commission on Form S-8, a registration form that permits securities issuers to 

register certain issuances of stock—but not stock paid in compensation for stock promotion services.  

3. In reality, as Tyrell and Schoengood knew, Tyrell never provided any business 

consulting services to Medifirst. Through Schoengood, Medifirst in fact issued stock to Tyrell as 

compensation for promoting Medifirst stock to potential investors through a stock promotion entity 

(“Promoter A”) affiliated with Tyrell.   

4. Because Form S-8 did not permit registration of stock issuances for such purposes, 

Schoengood and Tyrell, among other things, falsely represented to Tyrell’s brokerage firm that Tyrell 

was receiving Medifirst stock as compensation for business development services and that Tyrell 

was not involved in promoting Medifirst stock. 

5. Of the 20 million Medifirst shares he received, Tyrell later sold over 19 million 

shares to unwitting investors in the public market without registration for proceeds of approximately 

$125,000.  

6. In addition, from August through November 2017, Schoengood arranged, through 

another stock promoter (“Promoter B”), to have a third-party purchase Medifirst stock in exchange 

for cash payments in order to manipulate the market price of Medifirst stock.  

  

Case 2:21-cv-00979   Document 1   Filed 02/23/21   Page 2 of 23 PageID #: 2



3 

VIOLATIONS 

7. By virtue of the conduct alleged in this Complaint, Schoengood violated Sections 

5(a), 5(c), 17(a)(1) and 17(a)(3) of the Securities Act of 1933 (“Securities Act”) [15 U.S.C. §§ 77e(a), 

77e(c), 77q(a)(1) and 77q(a)(3)], Sections 9(a)(2) and 10(b) of the Securities Exchange Act of 1934 

(“Exchange Act”) [15 U.S.C. §§ 78i(a)(2) and 78j(b)], and Rule 10b-5 promulgated thereunder 

[17 C.F.R. § 240.10b-5]. 

8. By virtue of the conduct alleged in this Complaint, Medifirst violated Securities Act 

Sections 5(a), 5(c), 17(a)(1) and 17(a)(3) [15 U.S.C. §§ 77e(a), 77e(c), 77q(a)(1) and 77q(a)(3)], 

Exchange Act Section 10(b) [15 U.S.C. § 78j(b)], and Rule 10b-5 [17 C.F.R. § 240.10b-5]. 

9. By virtue of the conduct alleged in this Complaint, Tyrell violated Securities Act 

Sections 5(a), 5(c), 17(a)(1), 17(a)(2) and 17(a)(3) [15 U.S.C. §§ 77e(a), 77e(c), 77q(a)(1), 77q(a)(2) and 

77q(a)(3)], Exchange Act Section 10(b) [15 U.S.C. § 78j(b)], and Rule 10b-5 [17 C.F.R. § 240.10b-5]. 

10. Unless Defendants are restrained and enjoined, they will again engage in the acts, 

practices, transactions, and courses of business set forth in this Complaint or in acts, practices, 

transactions, and courses of business of similar type and object. 

NATURE OF THE PROCEEDINGS AND RELIEF SOUGHT 

11. The Commission brings this action pursuant to the authority conferred upon it by 

Securities Act Sections 20(b) and 20(d) [15 U.S.C. §§ 77t(b) and 77t(d)] and Exchange Act Section 

21(d) [15 U.S.C. § 78u(d)]. 

12. The Commission seeks a final judgment: (a) permanently enjoining Defendants from 

violating the federal securities laws and rules this Complaint alleges they have violated; (b) ordering 

Tyrell to disgorge the ill-gotten gains he received as a result of the violations alleged herein and to 

pay prejudgment interest thereon, pursuant to Exchange Act Section 21(d)(5) [15 U.S.C. § 78u(d)(5)] 

and Sections 6501(a)(1) and (a)(3) of the National Defense Authorization Act for Fiscal Year 2021, 

Case 2:21-cv-00979   Document 1   Filed 02/23/21   Page 3 of 23 PageID #: 3



4 

Pub. L. No. 116-283, to be codified at 15 U.S.C. §§ 78u(d)(3) and 78u(d)(7); (c) ordering 

Schoengood and Tyrell to pay civil money penalties, pursuant to Securities Act Section 20(d) [15 

U.S.C. § 77t(d)] and Exchange Act Section 21(d)(3) [15 U.S.C. § 78u(d)(3)]; (d) permanently 

prohibiting Schoengood from serving as an officer or director of any company that has a class of 

securities registered under Exchange Act Section 12 [15 U.S.C. § 78l] or that is required to file 

reports under Exchange Act Section 15(d) [15 U.S.C. § 78o(d)], pursuant to Securities Act Section 

20(e) [15 U.S.C. § 77t(e)] and Exchange Act Section 21(d)(2) [15 U.S.C. § 78u(d)(2)]; (e) permanently 

prohibiting Schoengood and Tyrell from participating in any offering of a penny stock, pursuant to 

Exchange Act Section 21(d)(6) [15 U.S.C. § 78u(d)(6)]; and (f) ordering any other relief the Court 

may deem just and proper. 

JURISDICTION AND VENUE 

13. This Court has jurisdiction over this action under Securities Act Section 22(a) 

[15 U.S.C. § 77v(a)] and Exchange Act Section 27 [15 U.S.C. § 78aa].   

14. Defendants, directly or indirectly, have made use of the means or instrumentalities of 

interstate commerce or of the mails in connection with the transactions, acts, practices, and courses 

of business alleged herein. 

15. Venue lies in this District under Securities Act Section 22(a) [15 U.S.C. § 77v(a)] and 

Exchange Act Section 27 [15 U.S.C. § 78aa]. Among other things, orders for the manipulative trades 

alleged here were placed in Nassau County in the Eastern District of New York. In addition, 

investors residing in the Eastern District of New York, including investors residing in Brooklyn or 

Queens, bought Medifirst stock on days that Tyrell sold shares into the public market and on days 

that Schoengood had arranged for manipulative trading in Medifirst stock. 

  

Case 2:21-cv-00979   Document 1   Filed 02/23/21   Page 4 of 23 PageID #: 4



5 

 

THE DEFENDANTS 

16. Schoengood, age 62, is a resident of Manalapan, New Jersey, and has been 

Medifirst’s CEO since at least 2011.    

17. Medifirst is a Nevada corporation with its principal office in Freehold, New Jersey. 

Medifirst currently claims to be marketing a “Laser Thermal Therapeutic Device.” From December 

2016 through November 2017 (the “Relevant Period”), Medifirst’s common stock was quoted under 

the symbol “MFST” on OTC Link, an interdealer quotation and trade messaging system operated by 

OTC Markets Group, Inc. During the Relevant Period, Medifirst’s common stock met the definition 

of a “penny stock” under Exchange Act Section 3(a)(51) [15 U.S.C. § 78c(a)(51)] and Rule 3a51-1 

thereunder [17 C.F.R. § 240. 3a51-1], in part because the stock traded below five dollars per share.  

18. Tyrell, age 36, is a resident of Huntington Beach, California. From at least 

December 2016 through May 2017, Tyrell was associated with Promoter A, a California-based stock 

promotion firm. 

LEGAL FRAMEWORK: RELEVANT REGISTRATION REQUIREMENTS 

19. Congress enacted the Securities Act to regulate the offer and sale of securities.  

20. In contrast to ordinary commerce, Congress enacted a regime of full and fair 

disclosure, requiring those who offer and sell securities to the investing public to provide sufficient, 

accurate information to allow investors to make informed decisions before they invest.  

21. A registration statement is a filing with the Commission making the required 

disclosures in connection with the registration of a securities offering (among other types of 

registration). Such registration statements provide public investors with information about the 

securities issuer and the offering.  

Case 2:21-cv-00979   Document 1   Filed 02/23/21   Page 5 of 23 PageID #: 5



6 

22. Securities Act Sections 5(a) and 5(c) prohibit the offer or sale of securities in 

interstate commerce without registration, absent a valid exemption from registration.    

23. Commission Form S-8 is a short-form registration statement to register certain 

offerings or issuances of a public company’s securities to people (“natural persons,” not entities) 

who provide “bona fide services” to the company as long as the services “do not directly or 

indirectly promote or maintain a market for the” securities. An issuer cannot use Form S-8 to 

register the issuance of stock in compensation for stock promotion services.  

24. A Form S-8 registration statement is not valid if it is used to register a stock offering 

that does not meet the requirements for using a Form S-8 registration statement. For example, a 

Form S-8 registration statement is not valid if it is used to register stock paid in compensation for 

stock promotion services.   

25. Under certain conditions, a person who receives stock through an issuance registered 

on a valid Form S-8 statement may resell that stock in the public market without the filing of any 

further registration statement. This is because most market transactions are covered by a common 

registration exemption.  

26. Sometimes companies issue stock in unregistered “private” transactions. In such 

cases, the stock certificate typically carries a restrictive legend preventing its resale in an unregistered, 

non-exempt transaction.  

FACTS 

I. DEFENDANTS ENGAGED IN A FRAUDULENT SCHEME TO SELL 
MEDIFIRST STOCK TO THE PUBLIC IN AN UNREGISTERED OFFERING.  

27. In the fall of 2016, Schoengood arranged to have the stock promotion firm Tyrell 

worked for, Promoter A, promote Medifirst stock by soliciting retail investors by telephone to 

purchase the stock in the public market. 

Case 2:21-cv-00979   Document 1   Filed 02/23/21   Page 6 of 23 PageID #: 6



7 

28. Schoengood arranged with Promoter A to use Tyrell as a conduit to receive Medifirst 

shares as compensation for Promoter A’s promotion of Medifirst stock.  

29. Under the arrangement, Medifirst’s issuance of shares was to be registered on 

Commission Form S-8 to enable Medifirst to issue the stock to Tyrell without any restrictive 

legend—that is, without any legend making clear that the shares cannot be resold into the public 

markets without meeting certain requirements. That way, Tyrell could immediately sell the shares he 

received to the public through market transactions. 

A. The Purported Consulting Agreement and Tyrell’s First 7.9 Million Shares 

30. On December 8, 2016, Medifirst and Tyrell executed a purported consulting 

agreement (the “Consulting Agreement”).  

31. Under the Consulting Agreement’s terms, Tyrell purported to act as a “business 

development” consultant to Medifirst for six months in exchange for 11 million shares of Medifirst 

common stock in an issuance that Medifirst would register on Form S-8.   

32. The Consulting Agreement purported to require Tyrell “not [to] conduct any 

meetings with any prospective financial investors” in Medifirst.  

33. Tyrell and Schoengood, on Medifirst’s behalf, signed the Consulting Agreement.  

34. On December 8, 2016, the same day Tyrell and Medifirst executed the Consulting 

Agreement, Medifirst filed a Form S-8 registration statement with the Commission, purporting to 

register Medifirst’s issuances of 32 million shares of Medifirst stock to employees and consultants, 

pursuant to Medifirst’s “MFST Equity Incentive Plan” (the “Incentive Plan”). 

35. At the time, the instructions to the Commission’s Form S-8 made clear to companies 

issuing stock that the Form S-8 could only be used to register securities issuances to people (“natural 

persons”) who provide “bona fide services” to the company issuing the stock when the services “do 

not directly or indirectly promote or maintain a market for the” company’s securities. 

Case 2:21-cv-00979   Document 1   Filed 02/23/21   Page 7 of 23 PageID #: 7



8 

36. Also on December 8, 2016, Schoengood signed a “Written Consent of the Sole 

Director of Medifirst Solutions, Inc.” (the “December 8 Consent”), authorizing the issuance of 11 

million shares of Medifirst stock to Tyrell.  

37. The December 8 Consent claimed that the shares were issued under the Incentive 

Plan “in connection with consulting services provided by [Tyrell].”  

38. The December 8 Consent also stated that the issuance of stock under the Incentive 

Plan “has been or will be registered on Form-8 with the SEC.” 

39. Also on December 8, 2016, in a letter emailed to Medifirst’s transfer agent (the 

“Transfer Agent”), Schoengood instructed the Transfer Agent to issue 7.9 million shares of 

Medifirst stock to Tyrell under the Incentive Plan.  

40. In his letter, Schoengood represented that the shares had been “issued for services 

rendered and registered pursuant to a registration statement on Form S-8” and therefore that the 

shares would be “free-trading and need not bear the standard 1933 Act legend,” apparently referring 

to a legend that would have made clear that the shares could not be sold or transferred without 

further registration or an exemption from registration.   

41. Schoengood’s letter bore a signature block identifying him as Medifirst’s chief 

executive officer. 

42. Tyrell then arranged to have the 7.9 million Medifirst shares deposited into his 

account at a brokerage firm (the “Brokerage Firm”). 

43. Specifically, on approximately December 9, 2016, Tyrell submitted an application to 

the Brokerage Firm to accept the deposit of 7.9 million Medifirst shares into his account at the 

Brokerage Firm.   

44. In his application, Tyrell represented to the Brokerage Firm that the Medifirst stock 

had been issued to him as compensation for “business development” services.   

Case 2:21-cv-00979   Document 1   Filed 02/23/21   Page 8 of 23 PageID #: 8



9 

45. On December 9, 2016, Tyrell emailed the Brokerage Firm’s registered representative 

assigned to Tyrell’s account (the “Registered Representative”).  

46. In his email to the Registered Representative, Tyrell claimed that he was “not 

involved or aware in [sic] any stock promotion with Medifirst.” 

47. On approximately the same day, Tyrell provided the Brokerage Firm with a copy of 

the Consulting Agreement, the December 8 Consent and Medifirst’s December 8 instructions to the 

Transfer Agent. 

48. On December 12, 2016, Tyrell sent an email to the Transfer Agent and to the 

Registered Representative, attaching a copy of a legal opinion letter dated December 8, 2017 (the 

“December 8 Opinion Letter”), addressed to the Transfer Agent,  

49. The December 8 Opinion Letter stated that 7.9 million Medifirst shares “may be 

issued to [Tyrell] without a restrictive legend” and that Tyrell “may sell the [Medifirst shares] free of 

any restrictions on transfer without registration under the Securities Act pursuant to the [Form S-8 

registration].”    

50. The December 8 Opinion Letter also instructed the Transfer Agent to issue the 

shares without a restrictive legend. 

51. The same day, Schoengood sent an email to Tyrell, directed to the Brokerage Firm.   

52. In his email, Schoengood claimed: “Mr. Tyrell has been engaged as a consultant to 

the company and as per our Consulting Agreement, his duties are not related to fundraising, [stock] 

market awareness, or Investor Relations.”  

53. Schoengood’s email bore a signature block identifying him as Medifirst’s president.  

54. About an hour later, Tyrell forwarded Schoengood’s email to the Brokerage Firm’s 

Registered Representative.   

Case 2:21-cv-00979   Document 1   Filed 02/23/21   Page 9 of 23 PageID #: 9



10 

55. Two days later, on December 14, 2016, the Transfer Agent issued 7.9 million 

Medifirst shares to Tyrell without a restrictive legend.   

56. As Tyrell had arranged, those shares were deposited into his Brokerage Firm 

account. 

B. Tyrell’s Second Installment of 3.1 Million Shares 

57. On January 17, 2017, in a letter emailed to the Transfer Agent, Schoengood 

instructed the Transfer Agent to issue an additional 3.1 million shares of Medifirst stock to Tyrell 

under the Incentive Plan, as already authorized by the December 8 Consent. 

58. In his letter, Schoengood represented that the shares had been “issued for services 

rendered and registered pursuant to a registration statement on Form S-8” and therefore that the 

shares would be “free-trading and need not bear the standard 1933 Act legend.”   

59. Schoengood’s letter bore a signature block identifying him as Medifirst’s chief 

executive officer. 

60. On approximately January 19, 2017, Tyrell provided the Transfer Agent with a legal 

opinion letter dated January 19, 2017 (the “January 19 Opinion Letter”), addressed to the Transfer 

Agent, that 3.1 million Medifirst shares “may be issued to [Tyrell] without a restrictive legend” and 

that Tyrell “may sell the [Medifirst shares] free of any restrictions on transfer without registration 

under the Securities Act pursuant to the [Form S-8 registration].”  

61. The January 19 Opinion Letter instructed the Transfer Agent to issue the shares 

without a restrictive legend. 

62. On approximately January 19, 2017, Tyrell submitted an application to the Brokerage 

Firm to accept his deposit of 3.1 million Medifirst shares into his account at the Brokerage Firm.   

63. In his application, Tyrell represented to the Brokerage Firm that the Medifirst stock 

had been issued to him as compensation for “business development” services. 

Case 2:21-cv-00979   Document 1   Filed 02/23/21   Page 10 of 23 PageID #: 10



11 

64. On approximately the same day, Tyrell provided the Brokerage Firm with copies of 

the January 19 Opinion Letter and Medifirst’s January 19 instructions to the Transfer Agent.   

65. Also on approximately the same day, Tyrell sent an email to the Brokerage Firm’s 

Registered Representative and claimed: “I Joshua Tyrell, am not involved in any stock promotion or 

capital raising with Medifirst.”   

66. On January 24, 2017, the Transfer Agent issued 3.1.million Medifirst shares to Tyrell. 

67. As Tyrell had arranged, those shares were deposited into his account at the 

Brokerage Firm. 

C. Tyrell’s Third Installment of 5 Million Shares  

68. On February 2, 2017, Medifirst and Tyrell amended the Consulting Agreement to 

provide for the issuance of an additional 5 million Medifirst shares to Tyrell. 

69. Schoengood, on Medifirst’s behalf, and Tyrell signed the amended agreement.  

70. On February 3, 2017, in a letter he emailed to the Transfer Agent, Schoengood 

instructed the Transfer Agent to issue an additional 5 million shares of Medifirst stock to Tyrell 

under the Incentive Plan and represented that the shares had been “issued for services rendered and 

registered pursuant to a registration statement on Form S-8” and therefore that the shares would be 

“free-trading and need not bear the standard 1933 Act legend.”   

71. Schoengood’s letter bore a signature block identifying him as Medifirst’s chief 

executive officer. 

72. On February 3, 2017, Schoengood provided the Transfer Agent with a “Written 

Consent of the Sole Director of Medifirst Solutions, Inc.” (the “February 3 Consent”) signed by 

Schoengood, authorizing the issuance of 5 million shares of Medifirst stock to Tyrell.   

73. The February 3 Consent claimed that the shares were issued under the Incentive 

Plan “in connection with consulting services provided by [Tyrell].”   

Case 2:21-cv-00979   Document 1   Filed 02/23/21   Page 11 of 23 PageID #: 11



12 

74. The February 3 Consent also stated that the issuance of stock under the Incentive 

Plan “has been or will be registered on Form-8 with the SEC.” 

75.  On approximately February 3, 2017, Tyrell provided the Transfer Agent with a legal 

opinion letter dated February 3, 2017 (“February 3 Opinion Letter”), addressed to the Transfer 

Agent, that 5 million Medifirst shares “may be issued to [Tyrell] without a restrictive legend” and 

that Tyrell “may sell the [Medifirst shares] free of any restrictions on transfer without registration 

under the Securities Act pursuant to the [Form S-8 registration].”   

76. The February 3 Opinion Letter instructed the Transfer Agent to issue the shares 

without a restrictive legend. 

77. On approximately February 6, 2017, Tyrell submitted an application to the 

Brokerage Firm to accept the deposit of 5 million Medifirst shares into Tyrell’s account at the 

Brokerage Firm.   

78. In his application, Tyrell represented to the Brokerage Firm that the Medifirst stock 

had been issued to him as compensation for “business development” services. 

79. On approximately February 6, 2017, Tyrell provided the Brokerage Firm with a copy 

of the February 3 Consent, Medifirst’s February 3, 2017 instructions to the Transfer Agent, and the 

February 3 Opinion Letter. 

80. On February 6, 2017, Tyrell sent an email to the Brokerage Firm’s Registered 

Representative and claimed: “I am not involved in any capital raising with [Medifirst].”   

81. On February 7, 2017, the Transfer Agent issued 5 million Medifirst shares to Tyrell. 

82. As Tyrell had arranged, the 5 million shares were deposited into his account at the 

Brokerage Firm. 

  

Case 2:21-cv-00979   Document 1   Filed 02/23/21   Page 12 of 23 PageID #: 12



13 

D. Tyrell’s Fourth Installment of 4 Million Shares  

83. On March 1, 2017, Medifirst and Tyrell amended the Consulting Agreement again to 

provide for the issuance of an additional 4 million Medifirst shares to Tyrell. 

84. On March 2, 2017, Schoengood signed a “Written Consent of the Sole Director of 

Medifirst Solutions, Inc.” (the “March 2 Consent”), authorizing the issuance of 4 million shares of 

Medifirst stock to Tyrell.   

85. The March 2 Consent claimed that the shares were issued under the Incentive Plan 

“in connection with consulting services provided by [Tyrell].”   

86. The March 2 Consent also stated that the issuance of stock under the Incentive Plan 

“has been or will be registered on Form-8 with the SEC.”  

87. On March 2, 2017, in a letter he emailed to the Transfer Agent, Schoengood 

instructed the Transfer Agent to issue an additional 4 million shares of Medifirst stock to Tyrell 

under the Incentive Plan, and represented that the shares had been “issued for services rendered and 

registered pursuant to a registration statement on Form S-8” and therefore that the shares would be 

“free-trading and need not bear the standard 1933 Act legend.”   

88. Schoengood’s letter bore a signature block identifying him as Medifirst’s chief 

executive officer. 

89. On that date, Tyrell provided to the Transfer Agent a legal opinion letter dated 

March 1, 2017 (the “March 1 Opinion Letter”), addressed to the Transfer Agent, that 4 million 

Medifirst shares “may be issued to [Tyrell] without a restrictive legend” and that Tyrell “may sell the 

[Medifirst shares] free of any restrictions on transfer without registration under the Securities Act 

pursuant to the [Form S-8 registration].”  

90. The March 1 Opinion Letter instructed the Transfer Agent to issue the shares 

without a restrictive legend. 

Case 2:21-cv-00979   Document 1   Filed 02/23/21   Page 13 of 23 PageID #: 13



14 

91. On approximately March 2, 2017, Tyrell submitted an application to the Brokerage 

Firm to accept the deposit of 4 million Medifirst shares into his account at the Brokerage Firm.   

92. In his application, Tyrell represented to the Brokerage Firm that the Medifirst stock 

had been issued to him as compensation for “Product Marketing and Ongoing Business 

Development.”  

93. On approximately March 2, 2017, Tyrell provided the Brokerage Firm with a copy of 

the March 2 Consent, Medifirst’s March 2, 2017 instructions to the Transfer Agent, and the March 1 

Opinion Letter. 

94. Also on March 2, 2017, Tyrell sent an email to the Brokerage Firm’s Registered 

Representative and again claimed: “I am not aware or involved in any stock promotion or capital 

raising with Medifirst Solutions, Inc.”  

95. On March 6, 2017, the Transfer Agent issued 4 million Medifirst shares to Tyrell. 

96. As Tyrell had arranged, the 4 million shares were deposited into his account at the 

Brokerage Firm. 

E. Tyrell’s Sales of the Shares and Phone Call with Schoengood 

97. From December 16, 2016 through May 1, 2017, Tyrell sold at least 19 million of the 

20 million Medifirst shares issued to him pursuant to the purported Consulting Agreement into the 

public market.  

98. Tyrell received about $125,000 in proceeds from these sales. 

99. On December 5, 2017, Tyrell spoke to Schoengood by telephone to discuss Tyrell’s 

stock promotion activities.  

100. In this call, Tyrell described how the salesmen at Promoter A called potential 

investors and started selling stock:  

[I]t takes a week or two for my guys to really start ramping up . . . start 
building the momentum. That’s how it kind of works with the phone calls.  

Case 2:21-cv-00979   Document 1   Filed 02/23/21   Page 14 of 23 PageID #: 14



15 

You start with one, two, ten people . . . they get other people. You talk about 
it, then they see it start trading, then they start jumping on it and chase it.  
You know how psychology works. 

II. SCHOENGOOD MADE MANIPULATIVE TRADES IN MEDIFIRST STOCK. 

101. Prior to 2017, Promoter B, another stock promoter, told Schoengood that Promoter 

B knew a broker who would buy Medifirst stock in exchange for a cash kickback (the “Buyer”). 

102. From August 1, 2016 through August 22, 2017, the price of Medifirst stock ranged 

from $0.012 to $0.0016 per share in reported transactions.   

103. During the same period, the daily trading volume of Medifirst stock ranged from 

61,000 shares to 64,882,000 shares in reported transactions. 

104. On six occasions from August 23, 2017 through November 2017, Schoengood 

arranged through Promoter B to have the Buyer purchase over 10.6 million shares of Medifirst stock 

in total in order to keep the price of Medifirst stock from falling.  

105. On August 23, 2017, the price of Medifirst stock opened at $0.0016 per share.   

106. That day, the lowest reported price at which Medifirst stock traded was $0.0015 per 

share.   

107. On August 23, 2017, Schoengood and Promoter B spoke by telephone.  

108. On that call, Schoengood asked Promoter B to arrange for the Buyer to buy 500,000 

shares of Medifirst stock.   

109. The same day, after the call, the Buyer purchased 500,000 Medifirst shares at $0.0017 

per share. 

110. That same day, the highest reported price at which Medifirst stock traded was 

$0.0017 per share.  

111. Two days later, on August 25, 2017, Schoengood spoke to Promoter B by telephone.  

Case 2:21-cv-00979   Document 1   Filed 02/23/21   Page 15 of 23 PageID #: 15



16 

112. On that call, Schoengood explained to Promoter B that he was using the Buyer’s 

purchases to keep Medifirst’s share price from falling: “I’d rather use your fire power when we need 

it to hold [Medifirst’s share price] . . . . I don’t want it to dip less than .0017 . . . . Let’s try and hold it 

there.” 

113. On September 11, 2017, the price of Medifirst stock opened at $0.0016 per share.   

114. That day, the lowest reported price for Medifirst stock was $0.0015 per share. 

115. On September 11, 2017, Schoengood spoke to Promoter B by telephone.  

116. On that call, Schoengood asked Promoter B to arrange for the purchase of Medifirst 

stock to “support” Medifirst’s stock price: Schoengood asked Promoter B to “contribute a little bit” 

and “make sure there’s a little support” for Medifirst’s share price.   

117. That day, following the call, the Buyer purchased 500,000 Medifirst shares at $0.0016 

per share. 

118. That day, the highest reported price for Medifirst stock was $0.0016 per share.   

119. The following month, on October 24, 2017, Schoengood spoke to Promoter B by 

telephone.  

120. On that call, Schoengood asked Promoter B to have the Buyer make some purchases 

as soon as possible “because I think we need a little boost.”   

121. The next day, on October 25, 2017, the price of Medifirst stock opened at $0.0012 

per share.  

122. The lowest reported price at which Medifirst stock traded that day was also $0.0012 

per share.   

123. On October 25, 2017, the Buyer purchased approximately 3.4 million shares of 

Medifirst stock—over 40% of the total reported volume of Medifirst shares that traded that day—at 

$0.0013 per share. 

Case 2:21-cv-00979   Document 1   Filed 02/23/21   Page 16 of 23 PageID #: 16



17 

124. The day after that, on October 26, 2017, the price of Medifirst stock opened at 

$0.0012 per share.  

125. The lowest reported price at which Medifirst stock traded that day was also $0.0012 

per share.  

126. On October 26, 2017, Schoengood again asked Promoter B to arrange for the Buyer 

to purchase Medifirst stock.   

127. Later on October 26, 2017, the Buyer purchased approximately 579,000 shares of 

Medifirst stock—almost 25% of the total reported volume of Medifirst shares that traded that day—

at $0.0013 per share. 

128. The next day, on October 27, 2017, the price of Medifirst stock opened at $0.0012 

per share.   

129. That day, the lowest reported price at which Medifirst stock traded was also $0.0012 

per share.   

130. On October 27, 2017, Schoengood spoke to Promoter B on the telephone.   

131. During the call, Schoengood told Promoter B that “[w]e want to get some [.0013] 

bids in there.”   

132. On the same call, Schoengood explained that he wanted “to tighten it up a little bit 

and then take some more of the [.0014]. If we hit the [.0012] then we are right back down.”   

133. Promotor B asked Schoengood: “So bid a little [.0013] and then take out some 

[.0014]?” Schoengood responded: “[E]xactly.”  

134. Later that day, the Buyer purchased approximately 2.8 million additional shares of 

Medifirst stock—over 70% of the total reported volume of Medifirst shares that traded that day—at 

$0.0013 per share. 

135. On November 13, 2017, Schoengood met with Promoter B. 

Case 2:21-cv-00979   Document 1   Filed 02/23/21   Page 17 of 23 PageID #: 17



18 

136. During the meeting Schoengood asked Promoter B about the Buyer and asked 

Promoter B: “Can we bring him back?”   

137. Promoter B explained that they would have to pay the Buyer kickbacks for prior 

trading.   

138. Schoengood replied: “Do me a favor, get him [the Buyer] going again.”  

139. On November 15, 2017, the price of Medifirst stock opened at $0.001 per share.  

140. That day, the lowest reported price at which Medifirst stock traded was $0.0008 per 

share.   

141. On November 15, 2017, the Buyer purchased another 3 million shares of Medifirst 

stock at $0.001 per share. 

142. On November 17, 2017, Schoengood met with Promoter B and gave Promoter B 

$1,600 to be paid as a kickback to the Buyer for the Buyer’s purchase of Medifirst shares. 

143. After the Buyer ceased buying Medifirst’s stock, its price declined steadily.   

144. By July 20, 2018, the trading day before Medifirst implemented a reverse stock split 

at a ratio of 1-to-1000 shares (meaning every 1,000 shares were consolidated into a single share), 

Medifirst’s closing stock price had dropped to $0.0002 per share.   

FIRST CLAIM FOR RELIEF 
Violations of Securities Act Sections 17(a)(1) and 17(a)(3) 

(All Defendants) 
 

145. Paragraphs 1 through 144 are realleged and incorporated by reference as if fully set 

forth herein. 

146. Schoengood, Medifirst and Tyrell, directly or indirectly, singly or in concert, in the 

offer or sale of securities, by the use of the means or instruments of transportation or 

communication in interstate commerce, or by use of the mails, (a) have employed, are employing, or 

are about to employ, devices, schemes, or artifices to defraud; and/or (b) have engaged, are 

Case 2:21-cv-00979   Document 1   Filed 02/23/21   Page 18 of 23 PageID #: 18



19 

engaging, or are about to engage in transactions, practices, or courses of business which operate, 

operated, or would operate as a fraud or deceit upon the purchasers of securities, in violation of 

Sections 17(a)(1) and 17(a)(3) of the Securities Act [Section 15 U.S.C. §§ 77q(a)(1) and 77q(a)(3)]. 

SECOND CLAIM FOR RELIEF 
Violations of Securities Act Section 17(a)(2) 

(Tyrell) 
 

147. Paragraphs 1–5, 9–100 are realleged and incorporated by reference as if fully set 

forth herein. 

148. Tyrell, directly or indirectly, singly or in concert, in the offer or sale of securities, by 

the use of the means or instruments of transportation or communication in interstate commerce, or 

by use of the mails, (a) has obtained, is obtaining, or is about to obtain, money or property by means 

of an untrue statement of a material fact or an omission of a material fact necessary in order to make 

the statements made, in light of the circumstances under which they were made, not misleading, in 

violation of Section 17(a)(2) of the Securities Act [Section 15 U.S.C. § 77q(a)(2)]. 

THIRD CLAIM FOR RELIEF 
Violations of Exchange Act Section 10(b) and Rule 10b-5 Thereunder 

(All Defendants) 
 

149. Paragraphs 1 through 144 are realleged and incorporated by reference as if fully set 

forth herein. 

150. Schoengood, Medifirst and Tyrell, directly or indirectly, singly or in concert, in 

connection with the purchase or sale of securities and by the use of the means or instrumentalities of 

interstate commerce, of the mails, or of the facilities of a national securities exchange, knowingly or 

recklessly (a) have employed, are employing or are about to employ devices, schemes and artifices to 

defraud; (b) have made, are making or are about to make an untrue statement of a material fact or to 

omit to state a material fact necessary in order to make the statements made, in the light of the 

circumstances under which they were made, not misleading; and/or c) have engaged, are engaging or 

Case 2:21-cv-00979   Document 1   Filed 02/23/21   Page 19 of 23 PageID #: 19



20 

are about to engage in transactions, practices or courses of business which have operated, operate or 

will operate as a fraud and deceit upon investors, in violation of Exchange Act Section 10(b) [15 

U.S.C. § 78j(b)] and Rule 10b-5 thereunder [17 C.F.R. §§ 240.10b-5]. 

FOURTH CLAIM FOR RELIEF 
Violations of Exchange Act Section 9(a)(2) 

(Schoengood) 
 

151. Paragraphs 1, 6–7, 10–17, and 101–144 are realleged and incorporated by reference 

as if fully set forth herein. 

152. Schoengood, directly or indirectly, singly or in concert, by use of the means or 

instruments of transportation or communication in, or the means or instrumentalities of, interstate 

commerce or by the use of the mails, knowingly or recklessly, is effecting, has effected or is about to 

effect, a series of transactions in securities with respect to such security creating actual or apparent 

active trading in such security, or raising or depressing the price of such security, for the purpose of 

inducing the sale of such security by others, in violation of Exchange Act Section 9(a)(2) [15 U.S.C. 

§78i(a)(2)]. 

FIFTH CLAIM FOR RELIEF 
Violations of Securities Act Sections 5(a) and (c) 

(All Defendants) 
 

153. Paragraphs 1–5 and 7–100 are realleged and incorporated by reference as if fully set 

forth herein. 

154. Schoengood, Medifirst and Tyrell, directly or indirectly, singly or in concert, in the 

offer or sale of securities, by the use of the means or instruments of transportation or 

communication in interstate commerce, or by use of the mails, (a) have sold securities without a 

registration statement being in effect as to those securities through the medium of a prospectus or 

otherwise; and (b) have offered to sell or offered to buy through the medium of a prospectus or 

Case 2:21-cv-00979   Document 1   Filed 02/23/21   Page 20 of 23 PageID #: 20



21 

otherwise a security, without a registration statement having been filed with the Commission as to 

such security, in violation of Securities Act Sections 5(a) and 5(c) [15 U.S.C. §§ 77e(a) and (c)]. 

PRAYER FOR RELIEF 

WHEREFORE, the Commission respectfully requests a Final Judgment: 

I. 

Permanently enjoining Defendants Schoengood, Medifirst, and Tyrell, and their agents, 

servants, employees, and attorneys, and all persons in active concert or participation with any of 

them who receive actual notice of the final judgment by personal service or otherwise, and each of 

them, from future violations of Securities Act Sections 5 and 17(a) [15 U.S.C. §§ 77e and 77q(a)], 

Exchange Act Section 10(b) [15 U.S.C. § 78j(b)] and Rule 10b-5 promulgated thereunder [17 C.F.R. 

§ 240.10b-5]; 

II. 

Permanently enjoining Defendant Schoengood, and his agents, servants, employees, and 

attorneys, and all persons in active concert or participation with any of them who receive actual 

notice of the final judgment by personal service or otherwise, and each of them, from future 

violations of Exchange Act Section 9(a) [15 U.S.C. §§ 78i(a)]; 

III. 

Ordering Defendant Tyrell to disgorge all ill-gotten gains he received directly or indirectly, 

with prejudgment interest thereon, as a result of his violations alleged in this Complaint, pursuant to 

Exchange Act Section 21(d)(5) [15 U.S.C. § 78u(d)(5)] and Sections 6501(a)(1) and (a)(3) of the 

National Defense Authorization Act for Fiscal Year 2021, Pub. L. No. 116-283, to be codified at 15 

U.S.C. §§ 78u(d)(3) and 78u(d)(7). 

  

Case 2:21-cv-00979   Document 1   Filed 02/23/21   Page 21 of 23 PageID #: 21



22 

IV. 

Ordering Defendants Schoengood and Tyrell to pay civil money penalties pursuant to 

Securities Act Section 20(d) [15 U.S.C. § 78t(d)] and Exchange Act Section 21(d)(3) [15 U.S.C. 

§ 78u(d)(3)]; 

V. 

Permanently prohibiting Defendant Schoengood from serving as an officer or director of 

any company that has a class of securities registered under Exchange Act Section 12 [15 U.S.C. 

§ 78l] or that is required to file reports under Exchange Act Section 15(d) [15 U.S.C. § 78o(d)], 

pursuant to Securities Act Section 20(e) [15 U.S.C. § 78t(e)] and Exchange Act Section 21(d)(2) 

[15 U.S.C. § 78u(d)(2)]; 

VI. 

Permanently prohibiting Defendants Schoengood and Tyrell from participating in any 

offering of a penny stock, including engaging in activities with a broker, dealer, or issuer for 

purposes of issuing, trading, or inducing or attempting to induce the purchase or sale of any penny 

stock, under Exchange Act Section 21(d)(6) [15 U.S.C. § 78u(d)(6)]; and  

  

Case 2:21-cv-00979   Document 1   Filed 02/23/21   Page 22 of 23 PageID #: 22



23 

VII. 

Granting any other and further relief as the Court may deem just and proper. 

JURY DEMAND  

 The Commission demands a trial by jury.  

Dated: New York, New York 
 February 23, 2021 
 
 

_/s/ Richard R. Best__________________   
Richard A. Best 

      Lara S. Mehraban 
Gerald A. Gross 
Preethi Krishnamurthy 
Eric M. Schmidt 

   
      SECURITIES AND EXCHANGE COMMISSION 
      New York Regional Office 
      Brookfield Place  
      200 Vesey Street, Suite 400 
      New York, New York 10281-1022  
      (212) 336-0116 (Krishnamurthy) 
      [email protected] 

Case 2:21-cv-00979   Document 1   Filed 02/23/21   Page 23 of 23 PageID #: 23